AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, according to data from a clinical trial. The Phase 2a clinical trial also met its main goals of showing that AIT-101…
Aural Analytics‘ speech analytics software app for amyotrophic lateral sclerosis (ALS), intended for use by researchers and doctors working in the disease, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The designation is meant to speed the development and review of…
I take pride in keeping a well-organized to-do list. Each day of the week has a set number of tasks, and each task is broken down into doable actions. It’s the “I’m under control and calm” approach. It’s perfect for someone like me who lives with ALS. But life’s…
An expanded access program for the experimental treatment SLS-005 has dosed its first participant, according to Seelos Therapeutics, the therapy’s developer. The expanded access program, or EAP, is an open-label study allowing access to SLS-005 for people with amyotrophic lateral sclerosis (ALS) who are…
AB Science has submitted its response to the European Medicines Agency (EMA), part of an ongoing review process aiming for the conditional approval of masitinib as an add-on oral therapy for amyotrophic lateral sclerosis (ALS). The Committee for Medicinal Products for Human Use (CHMP), an arm…
I am certain that many in my generation are familiar with the following words: “Raindrops on roses and whiskers on kittens/ Bright copper kettles and warm woolen mittens.” For the youngsters, those are lyrics from “My Favorite Things,” from the Broadway musical “The Sound of Music.” The song…
There are currently up to 18,000 people living with amyotrophic lateral sclerosis (ALS) in the U.S., with national costs likely to reach $1.02 billion each year, a study has found. Researchers also observed that men, white people, and veterans appear more likely to develop the disease. “However, large-scale, population-based…
The other evening, our daughter, Sara, read “Bread and Jam for Frances” aloud while I finished feeding dinner to my husband, Todd. He used to read this children’s book about a young badger with human qualities to Sara when she was little. In the book, Frances has an…
TDP-43, a protein that is known to have toxic effects in amyotrophic lateral sclerosis (ALS), is able to interact with RNA molecules carrying a chemical modification called m6A, and this chemical modification is increased in ALS nerve cells, a new study shows. The findings add to a growing body…
NeuroSense Therapeutics has joined researchers at Massachusetts General Hospital to study the impact of its investigational therapy PrimeC on key amyotrophic lateral sclerosis (ALS) processes. The collaboration will the headed by Ghazaleh Sadri-Vakili, director of the Neuroepigenetics laboratory at the MassGeneral Institute for Neurodegenerative Disease. Using a new…
